{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-029091","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.655859+00:00","generated_at":"2026-06-22T01:29:41.142935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Absci Q3 revenue $2.4M; cash burn guidance improved to ~$105M for 2022","bullets":["Cash and short-term investments $181.3M at Sep 30, down from $206.0M at Jun 30; operating cash use $19.0M in Q3.","Q3 revenue $2.4M vs $1.5M YoY, driven by Merck collaboration milestone and nsAA technology progress.","R&D expense $15.5M (+45% YoY); SG&A $11.4M; includes $2.7M severance charges.","Exceeded 2022 Active Program guidance: 10 signed YTD vs 8 target; total Active Programs now 17.","Appointed Andreas Busch as Chief Innovation Officer and Dan Rabinovitsj to Board; cash runway into late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-029091","json":"https://secwatch.observer/filing/0001628280-22-029091.json","markdown":"https://secwatch.observer/filing/0001628280-22-029091.md","text":"https://secwatch.observer/filing/0001628280-22-029091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022029091/0001628280-22-029091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022029091/absc-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:29:41.142935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ba532ab7e6716e8f7236a7d437b67e8d4626847","claim":"Absci Corp reported the quarter ended September 30, 2022 results: revenue $2.4 million. Guidance reaffirmed.","evidence_excerpt":"Total Revenue was $2.4 million for the third quarter of 2022, as compared to $1.5 million for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022029091/0001628280-22-029091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}